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Abstract
Muscle invasive bladder carcinoma is a complex, multifactorial disease caused by disrup-
tions and alterations of several molecular pathways that result in heterogeneous pheno-
types and variable disease outcome. Combining this disparate knowledge may offer
insights for deciphering relevant molecular processes regarding targeted therapeutic ap-
proaches guided by molecular signatures allowing improved phenotype profiling. The aim
of the study is to characterize muscle invasive bladder carcinoma on a molecular level by in-
corporating scientific literature screening and signatures from omics profiling. Public domain
omics signatures together with molecular features associated with muscle invasive bladder
cancer were derived from literature mining to provide 286 unique protein-coding genes.
These were integrated in a protein-interaction network to obtain a molecular functional map
of the phenotype. This feature map educated on three novel disease-associated pathways
with plausible involvement in bladder cancer, namely Regulation of actin cytoskeleton, Neu-
rotrophin signalling pathway and Endocytosis. Systematic integration approaches allow to
study the molecular context of individual features reported as associated with a clinical phe-
notype and could potentially help to improve the molecular mechanistic description of the
disorder.
Introduction
Bladder cancer (BC) presents with an estimate of 72,570 new cases diagnosed and 15,210
deaths across the United States [1] in the year 2013, clearly demonstrating a need for improved
diagnosis and therapy. Bladder cancer is the ninth most frequent malignancy with an approxi-
mate ratio of 5:1 with respect to non-muscle invasive versus muscle invasive phenotypes [2].
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Major confounders are smoking and other occupational exposures along with genetic predis-
positions, such as e.g. N-acetyltransferase 1 (NAT1), N-acetyltransferase 2 (NAT2) and gluta-
thione S-transferase µ1 (GSTM1) polymorphisms [3]. Though variable for bladder cancer
patients, initial symptoms include haematuria and flank pain, commonly represented during
advanced cancer stages caused by ureteric obstructions due to invasion of the bladder muscular
wall or ureter, together with recurrent urinary tract infections [4, 5]. Evidence suggests that ma-
lignant transformation of the bladder is multifactorial and a multitude of genes are involved in
the development of muscle invasive or non-muscle invasive phenotype [6, 7]. The major histo-
logical type is transitional cell carcinoma occurring in approximately 90% of diagnosed bladder
tumours (with the rest being mainly squamous cell carcinomas and adenocarcinomas), with
categories of non-invasive papillary (Ta) or flat (Tis), subepithelial invasive (T1), muscle inva-
sive (T2–T4) and metastatic (N+, M+) diseases, all differing in biology, progression character-
istics and hence clinical management. Majority of the cases are non-muscle invasive (Tis, Ta,
T1) and 10–15% are muscle-invasive tumours (T2–T4), with the latter associated with fast re-
currence and poorer prognosis based on progressing towards metastasis formation.
Cystoscopy is the gold standard with a reported sensitivity and specificity in the range of
62–84% and 43–98%, respectively [8]. Due to the invasive nature of the procedure, but also for
adding accuracy in the detection, biomarkers assessed in blood or urine are considered as bene-
ficial for supporting clinical assessment [9]. This is also relevant for disease prognosis as bio-
markers measured at the DNA, RNA and/or protein levels provide the potential to choose best
surveillance measures and treatment regimens for specific patient populations regarding halt-
ing the development of muscle invasive disease [10]. Treatment of papillary and non-muscle
invasive high-grade carcinoma involves endoscopic transurethral resection of visible tumours
followed by adjuvant treatment with intravesical instillation therapy (Mitomycin/Epirubicin or
Bacillus Calmette-Guerin (BCG)) depending on the estimated risk for progression. Irrespective
of aggressive treatment and vigorous follow-up, 70% of these tumours recur, and 25% of high-
grade non-muscle invasive cancers progress into invasive phenotypes [2, 11].
The comparison of the genetic characteristics of muscle-invasive and non-invasive tumours
revealed that non-invasive tumours over-express HRAS and FGFR3 or produce highly activat-
ed forms of these proteins. As a result, the Ras/MAPK pathways are up-regulated in non-
invasive tumours [12]. Muscle-invasive BC is associated with alterations of p53, retinoblastoma
protein (RB1) and tumour suppressors controlling cell cycle processes, in addition to elevated
expressions in epidermal growth factor receptor (EGFR), human epidermal growth factor re-
ceptor 2 (HER2/ErbB2), matrix metallopeptidase 2 (MMP2) and MMP9 and deletions in
p16Ink4a and P15Ink4b [3].
High-throughput experimental platform technologies ranging from genomic sequencing to
proteomic and metabolomic profiling are now being used for molecular characterization of
clinical phenotypes [13–19]. A variety of datasets have become available e.g. in Array Express/
Gene Expression Omnibus (GEO) for transcriptomics, Human Proteinpedia for proteomics, or
in large data consolidation platforms such as GeneCards [20]. In regard to disease specific
omics data, valuable general sources in oncology include TCGA (http://cancergenome.nih.gov/
), Oncomine [21], and OMIM [22]. Though omics profiling has provided an abundance of
data, technical boundaries involving incompleteness of the individual molecular catalogues to-
gether with the static representation of cellular activity limits the insights on molecular process-
es and their interaction dynamics [23–25]. Despite these challenges, omics-based profiling has
significantly advanced bladder cancer research, providing the basis for an integrative analysis
approach in delineating a more comprehensive overview of molecular processes and pathways
that characterize variations of muscle-invasive urothelial carcinoma [12].
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On the effector level, proteins interact and co-operatively form specific molecular processes
and pathways. Intermolecular interactions include various types being represented as networks
(graphs) with molecular features denoted as nodes (vertices) together with their interactions
(edges). A large number of biological pathway resources has become available, including
KEGG [26], PANTHER [27], REACTOME [28] and AmiGO [29] described in PathGuide
(http://www.pathguide.org/), all displaying well-defined human molecular metabolic and sig-
nalling pathways together with disease-specific pathways (e.g. pathways in cancer). Molecular
features being identified as associated with bladder cancer can be interpreted on the level of
such pathways, adding to a functional interpretation of molecular feature sets characterizing
the phenotype.
To add to our understanding of muscle-invasive bladder carcinoma (MIBC), we derived a
phenotype-specific network model (interactome) by integrating omics signatures characteriz-
ing MIBC, reported in scientific literature and databases. Our procedure incorporated scientific
literature screening and signatures from omics profiling, resulting in 1,054 protein-coding
genes being associated with MIBC, further consolidating to 286 genes on the interactome level.
The results display deriving a systems-level model for molecular phenotyping of bladder cancer
muscle invasion, presented as multiple affected pathways.
Materials and Methods
Data sources for characterizing bladder cancer pathophysiology
For consolidating molecular features associated with muscle invasive bladder cancer, NCBI
PubMed, Web of Science, Google Scholar and the omics repositories Gene Expression Omni-
bus (GEO) [30] and ArrayExpress [31] were queried. The keywords for the literature search in-
cluded “bladder OR urothelial OR transitional cell” AND “neoplasm OR tumor OR
carcinoma” AND “muscle” AND “invasOR aggressOR progressOR inflammation” (Data-
base version of April, 2014). By construction this search query focused specifically on muscle
invasive bladder neoplasm. For extracting protein-coding genes associated with these publica-
tions gene-2-pubmed as provided by NCBI was used [32]. The list of publications relevant to
bladder cancer muscle invasion was isolated from the complete list of papers indexed in
PubMed along with the associated gene IDs (ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2pubmed.gz). Profiling experiments were further screened for adequacy in sample size
(at least 50 samples included in study design), magnitude of differential abundance (>2-fold
change) and the specific phenotypic conditions; T1, T2a/b, T3a/b, T4a/b (Figs. 1 and 2). In addi-
tion, only papers mentioning the keywords “molecular” and “biomarker” were retained for de-
riving the literature mined MIBC molecules and pathways.
Interaction data and induced subgraph
Protein interaction information was obtained by querying IntAct [33], BioGRID [34], and
Reactome [28] leading to a total of 233,794 interactions covering 13,907 protein-coding genes
within the human interactome (Databases in version of April, 2014). Mapping the MIBC asso-
ciated molecular features on this consolidated interaction network [13] provided an MIBC-
specific induced subgraph. MIBC associated features not connected to at least another such fea-
ture were disregarded from further analysis.
Functional analysis
Cytoscape’s plug-ins ClueGO and CluePedia was used to identify pathways that are being
over-represented in the set of features located in the induced subgraph [35, 36]. KEGG pathway
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terms served as the clustering criterion using a two-sided hypergeometry test followed by Bon-
ferroni correction (significance level of 0.05) for identifying significantly affected pathways.
General disease pathways (such as pathways in cancer, miRNA’s in cancer, bladder cancer etc.)
were discarded to obtain a set of generic pathway terms [13].
Protein coding gene selection based on literature mining
From the set of MIBC-associated protein-coding genes, each gene symbol was evaluated for
being a member of the MIBC pathway set. The evidence of identified pathways and extracted
genes involved in MIBC was assessed based on the level of annotation depth, defined as the
number of individual studies identifying such protein-coding genes as involved in MIBC. Spe-
cifically, such evidence was derived from metadata available in PubMed. Gene-2-pubmed was
used for linking the molecules contained in the induced subgraph to publications relevant to
bladder cancer muscle invasion. The quality of publications obtained for each molecule was as-
sessed based on manual reviewing. Only papers where a direct link of the molecule to bladder
cancer muscle invasion was proven were retained. For the entire pathway set, the ratio between
the number of molecules being linked to at least one urinary bladder neoplasm publication and
the number of features in the pathway was computed and used for relevance ranking. For indi-
vidual protein-coding genes identified in literature the number of linked urinary bladder neo-
plasm publications was used as relevance ranking criterion.
Results
Data Mining
Mining of published articles and omics repositories led to a collection of 285 references after
manual screening (Fig. 1). This screening was performed to discard duplicated studies retrieved
Figure 1. Data assembly workflow. PubMed, Google Scholar andWeb of Science literature analysis and Omics data source screening with focus on
transcriptomics. From the 4263 abstracts screened 3979 articles were excluded not specifically focusing on muscle-invasive bladder cancer phenotype
(stages T2–T4). 188 studies out of 285 articles were discarded, as these did not meet required study designs and 2-fold change in magnitude of differential
abundance of identified features. This restriction resulted in 1,279 protein-coding genes and was further used in the systems based analysis for MIBC.
doi:10.1371/journal.pone.0116404.g001
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from the varying repositories as well as articles not explicitly focusing on muscle-invasive blad-
der carcinoma. All molecular features were converted to their official gene symbol by using the
UniProt ID Mapping service [37]. The resulting set of references yielded in total 1,279 proteins
of which 1,054 were unique protein-coding genes associated with MIBC (S1 Table). For collect-
ing specifically proteins involved in MIBC, we further screened these 285 articles with the key-
words (“molecular and biomarker”) to retrieve 122 proteins that had a tag “biomarker”
mentioned in these articles (S2 Table). This restriction helped in discarding general articles
containing gene symbols that were not associated to the muscle-invasive phenotype. The same
set of 285 articles was used to collect all pathways connected to bladder carcinoma. Thus, 11
pathways reported in the literature to be associated with bladder cancer were obtained (S3
Table).
The largest number of features associated with MIBC resulted from transcriptomics with a
total of 716 gene symbols. Metabolites were mapped to protein coding genes using the Human
Metabolome Database (HMDB) [38] and provided 329 gene symbols. The miRNAs from the
transcriptomics studies were mapped to their respective gene targets using the service from
miRbase [39, 40]. In addition, DNA-methylation studies provided 77 gene symbols respective-
ly. DNA-mutation studies reported 35 gene symbols. Scientific literature analysis provided 178
protein-coding genes, of which 122 were further annotated as indicators of muscle-invasive
bladder cancer. The detailed information on all differentially expressed molecular features is
available in S2 and S4–S8 Tables.
Data Source Overlap
With respect to the feature set overlap, 52 gene symbols were identified in both, literature min-
ing and individual omics signatures (S1 Table). Of the 1,054 unique gene symbols, 716 protein-
coding genes were from transcriptomics studies, 13 of these were found on DNA-methylation
level, 13 on DNA-mutation level, and 19 on the metabolome level (Fig. 2a). This relatively
weak overlap on the level of individual features, however, is a frequent finding in cross-Omics
data consolidation, in part stemming from constraints of applied methods, and different sam-
ple matrices under investigation in each case [41, 42].
Induced Subgraph
To increase evidence in regard to the association of molecular features with MIBC we included
protein-interaction information as a filter mechanism, i.e. combining evidence from statistical
analysis with biological (interaction) data. For this analysis, the molecular feature set was re-
duced from 1,054 unique protein coding genes to 592 gene symbols. The reduction in the pro-
tein list was mainly caused because the protein coding genes indirectly linked from
metabolomics and miRNA profiling were not incorporated in the pathway analysis due to low
evidence linking to respective targets and enzymes. Further disregarding features not showing
interactions to other members of the MIBC set resulted in 286 protein-coding genes repre-
sented on the muscle invasive bladder cancer-specific subgraph. The list of the initial 1,054 pro-
teins, the 592 proteins disregarding metabolomics data and miRNA screens, and the list of 286
proteins that form protein-protein interactions in the MIBC subgraph is available in S9 Table.
This set of protein-coding genes with strong evidence regarding association with MIBC and
holding interactions to other such features was included in pathway analysis (Fig. 2b).
Pathway enrichment
KEGG pathway enrichment analysis of the MIBC molecular feature set represented on the in-
duced subgraph utilizing ClueGO and CluePedia resulted in 15 molecular pathways being
Interactome and Muscle-Invasive Bladder Cancer
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significantly affected in the context of muscle invasive bladder carcinoma (Fig. 3, S3 Table). In
detail, 11 of these pathways were previously identified in literature, in addition to 4 presumably
novel pathways that resulted from the interactome analysis.
The network in Fig. 3 represents each pathway as individual node, while the edges between
pathways denote an approximation of biological interaction between the pathways based on
the cross-pathway feature overlap. This pathway map allowed evaluating the functional context
of the 122 literature-mined protein candidates in the context of MIBC.
Fig. 3 describes pathway terms enriched using the MIBC-specific induced subgraph. Catego-
rizing the pathway terms in known and novel pathways according to literature, we obtained
11 pathways that were reported in the literature, namely Focal adhesion consisting of 40 pro-
tein coding genes, MAPK signalling pathway with 26, ECM-receptor interaction and Cell cycle
with 17 features each, p53 with 16, Tight junction and Adherens junction with 15 features
each, Leukocyte transendothelial migration with 12, VEGF signalling pathway with 11, and
Gap junction containing 10 protein coding genes (see S3 Table). The novel set of pathways that
were enriched in the analysis contained 4 pathway terms of which 3 pathways were resting on
significant association with the muscle-invasive bladder cancer phenotype, namely Regulation
of actin cytoskeleton holding 18 protein coding genes, Endocytosis with 16 and Neurotrophin
signalling with 13 (Table 1). The highest overlap in gene symbols was found between regulation
of actin cytoskeleton pathway and serotonergic synapse containing ARAF, HRAS, RAF1 and
MAPK1, neurotrophin signalling pathway and regulation of actin cytoskeleton pathway, con-
taining MAPK1, RAF1 and HRAS. The overlap of gene symbols between endocytosis and regu-
lation of actin cytoskeleton pathway was FGFR3, EGFR and HRAS, while those between
Figure 2. Feature set Overlap. A. Redundant features were discarded from 1,279 protein coding genes resulting in 1,054 unique features.The overlap
between individual omics studies and literature were calculated. B. The 1,054 protein coding genes were further reduced to 592 by discarding enzymes
linked to metabolites as well as miRNA targeted gene symbols, further included for deriving the induced MIBC subgraph resting on BioGRID, IntAct and
Reactome protein interaction information.
doi:10.1371/journal.pone.0116404.g002
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Figure 3. Muscle Invasive Bladder carcinoma interactome, set of 286 protein coding genes.Nodes in orange denote pathways identified as relevant in
both literature and enrichment analysis, nodes in blue depicts pathways of relevance according to enrichment analysis. Node size scales with the number of
gene symbols encoded in each pathway term.
doi:10.1371/journal.pone.0116404.g003
Table 1. KEGG pathways signiﬁcantly associated with muscle invasive bladder carcinoma utilizing the gene set embedded in the induced
subgraph.
KEGG Pathway Name Number of MIBC
features
Bonferroni
corrected p-value
Overlapping protein-coding genes
Regulation of actin
cytoskeleton
18 0.005874 PDGFA, FGF1, RAF1, EGFR, ACTN4, FGFR1, ITGB4, FGFR3, MYLK, HRAS,
ACTN1, FGF2, ITGA5, ARAF, FN1, MAPK1, ACTB, ITGA6
Endocytosis 16 0.0344 EGFR, MDM2, TGFBR2, FGFR3, HRAS, ERBB3, TGFB3, TGFBR1, ERBB4,
CAV1, MET, PRKCZ, KDR
Neurotrophin signalling
pathway
13 0.01022 BDNF, RAF1, BAD, HRAS, ABL1, GAB1, BCL2, TP53, BAX, YWHAZ, JUN,
MAPK1
Serotonergic synapse 12 0.0278 RAF1, GNAI3, PRKCG, ITPR3, HRAS, CASP3, PTGS2, DUSP1, ARAF,
MAPK1, PRKCA
Pathway terms, total number of MIBC features associated with the term, Bonferroni corrected p-value and speciﬁc gene symbols found overlapping
amongst the 4 pathway terms.
doi:10.1371/journal.pone.0116404.t001
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neurotrophin signalling pathway and serotonergic synapse were HRAS, RAF1 and MAPK1.
The least overlap of gene symbols between pathways was seen for neurotrophin signalling
pathway and endocytosis, only sharing HRAS. Subsequently, there was no protein-coding gene
overlapping for endocytosis and serotonergic synapse.
We performed an additional pathway enrichment analysis that involved an alternative set of
gene symbols. From the full set of protein coding genes (707 molecules excluding metabolite
and miRNA targetted gene symbols), we restricted to members being present in more than one
study type (e.g. ERBB2 was found in proteomics, mRNA and literature mining). This restric-
tion resulted in 72 gene symbols, again forwarded to pathway enrichment analysis. Fig. 4 de-
tails pathway terms enriched using this reduced set of protein coding genes. Seven pathway
terms were enriched in this analysis. Categorizing these pathway terms into known from litera-
ture and novel pathways, 5 pathway terms were reported in literature and 2 pathways were
novel findings. The 5 previously known pathway terms included Focal adhesion, Cell cycle,
and p53 signalling pathway, ECM-receptor interaction, and ErbB signalling (S10 Table). In re-
gard to the 2 novel pathways that were enriched from this analysis, the pathway terms were
T cell receptor signaling pathway and GnRH signaling. Table 2 details all pathways with their
overlapping gene symbols that were retrieved from this analysis. Regarding pathways with lit-
erature evidence the enrichment resting on the 72 gene symbols had a full overlap with the
Figure 4. Muscle Invasive Bladder carcinoma pathway enrichment, set of 72 protein coding genes.Nodes in orange denote pathways identified as
relevant in both literature and enrichment analysis; nodes in blue depict pathways of relevance according to enrichment analysis. The size of each node size
scales with the number of gene symbols encoded in each pathway term.
doi:10.1371/journal.pone.0116404.g004
Interactome and Muscle-Invasive Bladder Cancer
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15 pathway terms retrieved using the induced subgraph MIBC feature set. The 2 pathways not
showing an overlap were the novel pathways resting on the second gene set namely T cell re-
ceptor signalling and GnRH signalling (Fig. 4, S3 and S10 Tables).
Discussion
Understanding the molecular pathophysiology of muscle-invasive bladder carcinoma and re-
vealing the network of pathways involved in muscle invasion could lead to targeted therapy. In
addition, addressing specific dys-regulated pathways linked to progressive disease holds the
promise of supporting an improved, biomarker-based risk assessment followed by stratified
clinical intervention [2]. High throughput screening platforms have provided a wealth of infor-
mation in describing the molecular status reflecting a clinical phenotype, including bladder car-
cinoma [43, 44]. Experiments based on expression profiling using microarrays, and
fractionation techniques coupled to mass spectrometry utilizing tissue and urine as sample ma-
trix have supported molecular pathway-based discovery in bladder muscle invasive neoplasms
[12, 45]. The present study intended to characterize muscle invasive bladder carcinoma by in-
corporating scientific literature screening and signatures from omics profiling further linked in
an interaction context, resulting in a set of 286 protein-coding genes. Such analysis on the level
of networks and pathways was chosen with the expectation that miscellaneously found pheno-
typic features consolidate on a pathway level, under the assumption that they are functionally
linked and collectively affect the disease phenotype.
High-throughput DNA sequencing can yield erroneous data [46]. MS based proteomics ex-
periments generate enormous datasets that need to be carefully assessed [47].
Biological pathway databases play an essential role in annotating protein-coding genes re-
sulting from high-throughput profiling approaches. There are approximately 547 pathway da-
tabase resources available as listed in PathGuide (http://www.pathguide.org/). Albeit there are
several well curated and reliable pathway database resources as also described by our group
[48], significant efforts have been taken to expand biological pathway coverage beyond any sin-
gle pathway data source. This is frequently carried out by integrating different sources in order
to build high quality integrative pathway models without sacrificing data quality. However, bi-
ological data integration from heterogeneous sources has been challenging due to variability at
the syntactic and semantic level. Syntactic variability is due to heterogeneity of molecular fea-
ture and pathway data formats, representation schemas and retrieval methods. Semantic
Table 2. KEGG pathways signiﬁcantly associated with MIBC according to gene symbols found in more than one omics study type.
KEGG Pathway Name Number of
features
Bonferroni corrected p-
value
Overlapping protein-coding genes
Focal adhesion 16 2.31E-011 COL3A1, HRAS, CCND1, COL11A1, FN1, THBS1, JUN, COL5A1,
RAF1, EGFR, COL1A2
Cell cycle 7 0.00141 CCND1, TP53, CDK4, CDKN2A, CDKN1A
p53 signaling pathway 6 4.17E-04 CCND1, THBS1, TP53, CDK4, CDKN2A, CDKN1A
ErbB signalling pathway 6 0.00172 HRAS, JUN, RAF1, CDKN1A, EGFR
ECM-receptor interaction 6 0.00151 COL3A1, COL11A1, FN1, THBS1, COL5A1, COL1A2
GnRH signalling pathway 5 0.0360 HRAS, JUN, RAF1, EGFR
T cell receptor signalling
pathway
5 0.048 HRAS, JUN, CDK4, RAF1
Pathway terms, number of molecules associated with the term, Bonferroni corrected p-value and speciﬁc gene symbols found overlapping amongst the 7
pathway terms.
doi:10.1371/journal.pone.0116404.t002
Interactome and Muscle-Invasive Bladder Cancer
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variability is due to incompatible pathway names, signalling event representations and molecu-
lar identifiers. For example, different pathway databases may choose to provide information on
post-translation modifications, interacting proteins within a complex, or cellular location.
Hence all these limitations have inhibited the growth of high quality integrative pathway mod-
els [49–51].
Another issue that arises when aiming to integrate data from different omics platforms is
that conflicting results can be obtained. For example in some muscle invasive tumours pre-
sented in [52], transcriptomics analysis proved that the mRNA level of EGFR is up-regulated,
whereas proteomic analysis did not show differential expression at the protein level. One expla-
nation for such discrepancy may be translational regulation.
In KEGG, biological pathway categorization is currently available for several human key cel-
lular processes [13]. Mapping MIBC-specific features (corrected on the level of the induced
subgraph utilizing protein interaction information) to KEGG and performing enrichment
analysis provided a total of 15 pathways (4 novel and 11 cited in published studies). 68 of 122
literature-mined protein candidates of relevance in muscle-invasive bladder cancer were
identified as members of the identified pathways. This enabled to comprehensively rank path-
ways allowing the shortlisting of terms being individually discussed in the specific context of
MIBC.
We focused on expanding our knowledge on muscle invasive urothelial neoplasm affected
at the molecular level by comprehensively mapping available molecular datasets to pathways to
build an interactome network utilizing public domain data sources. By differentiating the path-
ways based on previously described pathways and novel ones we obtained 11 modules that
were known in context of bladder cancer muscle-invasion and 4 novel pathways. In respect to
the previously known urothelial bladder muscle-invasive carcinoma pathways, our analysis re-
trieved pathways such as MAPK signalling pathway, ErbB signalling pathway, cell-cycle path-
ways and VEGF signalling pathway, hence confirming the systems-level approach for the
particular phenotype [3, 12, 53, 54].
On the other hand, the interactome results also retrieved significant pathways comprising
of signalling pathways, cytoskeleton remodelling pathways and neuromuscular junctions.
Three molecular pathways were highly significant from the analysis, namely regulation of actin
cytoskeleton, neurotrophin signalling pathway and endocytosis.
Neurotrophins are a class of closely related proteins that control the function, survival and
development of neurons and have the potential to activate tropomyosin-related kinase (Trk)
family of receptors and down regulate tumour necrosis factor superfamily (p75NTR) through
which PI3K/Akt, Ras/Raf/MAP kinase, NF-kappa B and Jun kinase signalling pathways are
triggered. Trk-receptors with neurotrophin ligands have been identified as initiating tumour
progression, and the signalling pathway neurotrophins-Trk has been reported as a target for
therapeutic intervention in hormone-refractory prostate cancer (HRPC) and in human astro-
cytomas, and potentially could play a role in urothelial carcinoma [55–58]. Endocytic pathways
represent multiple aberrations in human neoplasms by being tightly and bi-directionally con-
nected to signalling pathways that could indicate malignant transformations of the tumours.
One of its regulators, DAB2, has also been reported to be prominent in advanced stages of
urothelial cancers, where a decreased expression of the molecule could be observed in metastat-
ic stages, and has been associated with high probabilities of recurrence and bladder carcinoma
mortality [59–61]. Deregulation of actin bound proteins, namely p38β, ATF3 and Rho family
of small GTPases which are involved in cytoskeletal remodelling, causes aberrant cell motility
that leads to the muscle-invasive and metastatic phenotypes in cancer [62–65]. Our analysis
highlights the role of the cytoskeletal remodelling pathway that contains integrins, cadherins
and adhesion proteins. The respective molecular pathways discussed above open new avenues
Interactome and Muscle-Invasive Bladder Cancer
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for further investigation of urothelial muscle-invasive carcinoma. One enriched pathway that
did not show any direct relation to bladder cancer was serotonergic synapse that contained
12 protein molecules (S3 Table).
The bioinformatics approach reported here involved integrating available public domain
data sets in context of bladder muscle-invasive carcinoma on an interaction network, and fur-
ther mapping them to biological pathway sources to reveal 15 pathways as being affected in
progressive disease. Eleven from these pathways were discussed previously in the context of
MIBC. It should be taken into account that while using such computational techniques to inte-
grate molecular signatures from varying resources, certain technical issues regarding the use of
appropriate global identifier need to be considered. In our approach, we discarded metabolite
and micro-RNA targets for the pathway enrichment analysis (i.e. gene symbols mapped from
metabolomics and miRNA data, service provided by HMDB and miRBase), resulting in 592
features from the total of 1,054 protein coding genes. This is mainly driven by hampered trans-
lation of metabolite and microRNA profiles to the level of involved protein coding genes, be it
on the target or enzyme level. In regard to genomics and epigenetics, we only incorporated
those gene symbols that contained epigenetic information on the protein/mRNA abundance
levels for the interactome analysis.
On the other hand, the two pathway terms GnHR receptor and T cell receptor signalling
pathways found as enriched on the basis of the 72 gene symbols being multiply identified
in, were not retrieved from the analysis resting on the full set of 286 features being derived
from the induced subgraph. Data evidence and selection biases clearly affect results of such
integrated analysis demanding strict quality control of input data sets as followed in our
study.
Apparently, each individual functional context highlights specific aspects of bladder cancer
pathophysiology, but only providing limited characterization of clinical outcome on the cohort
level.
In summary, automated data retrieval from the literature resulted in a first collection of mo-
lecular features associated with MIBC, and, complementing with omics profiling data, allowed
augmenting a mechanistic (pathway) map linked to MIBC. From the cross-sectional nature of
the underlying molecular feature collection no direct conclusion can be drawn regarding the
prognostic relevance of individual pathways. However, deriving bladder cancer-associated pro-
tein coding genes on the basis of such pathway maps provides a systematic foundation for ex-
perimental analysis regarding association with development of muscle-invasive disease. We are
confident that this approach can form the basis to rational selection of biomarkers for enabling
targeted analysis of potentially relevant key molecules.
Conclusions
Our results suggest that there is a complex interplay between interacting pathways that charac-
terizes the muscle invasive phenotype of invasive bladder cancer. We developed an integrated
molecular model of muscle invasive bladder cancer to allow selecting protein-coding genes on
the pathway level aimed at capturing a set of pathways of potential relevance in tumour pro-
gression. Further experimental validation of Neurotrophin signalling pathway, Regulation of
actin cytoskeleton and Endocytosis with respect to disease progression and treatment response
in muscle-invasive bladder carcinoma is indicated.
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on the frequency of occurence. Combing all protein coding genes resulted in 1,054 unique pro-
tein coding genes.
(XLS)
S2 Table. Data Inclusion for Muscle Invasive Bladder Carcinoma—Non-Redundant Fea-
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(XLS)
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miRNA targets pertaining to the muscle-invasive phenotype (T2–T4) of bladder carcinoma
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(XLS)
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available studies.
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S8 Table. Data Inclusion for Muscle-Invasive Bladder Carcinoma—DNAMutation. Provid-
ed are protein coding genes with significant levels of mutations pertaining to muscle-invasive
phenotype (T2–T4) of bladder carcinoma and PubMed identifiers.
(XLS)
S9 Table. Protein coding genes involved in the induced Subgraph. Provided are the MIBC-
asociated gene symbols in three different columns; a. 1,054 unique gene symbols from initial
consolidation, b. 592 gene symbols excluding enzymes from metabolite signatures as well as
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miRNA targets c. 286 gene symbols that formed the induced subgraph, and d. interaction in-
formation among the 286 gene symbols.
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S10 Table. Enriched Pathways in context of Urothelial Muscle-Invasive Carcinoma using
the 72 molecules that were found in more than one omics study. 7 pathway terms were en-
riched. The set of protein coding genes included is listed in sheet 2. Sheet 3 and 4 list known
and novel pathways together with the number of protein coding genes assigned and Bonferroni
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